

*Seizure* 1997; **6**: 157–158

## ANNOUNCEMENTS

# Managing Epilepsy: A Workshop for People with Epilepsy and their Families

**22nd International Epilepsy Congress**  
**27–28 JUNE 1997**  
**Trinity College, Dublin**

**Organised by the International Bureau for Epilepsy**

For people with epilepsy and other members of their family, this workshop will bring together experts in the field to discuss important issues in managing epilepsy today.

The workshop will cover:

- what is epilepsy
- the needs of people with epilepsy

- educational and employment issues
- conventional and alternative treatments

**Cost:** £120 per person, to include registration, accommodation, lunch, tea and coffee.

**For further information, contact:**

Ann Jacoby  
University of Newcastle upon Tyne, UK  
Tel: 00 44 191 222 7046  
Fax: 00 44 191 222 6043  
e-mail: [ann.jacoby@ncl.ac.uk](mailto:ann.jacoby@ncl.ac.uk)

Jacqui Berkeley  
Incentive Conference Ireland  
Tel: 00 353 1 667 1711  
Fax: 00 353 1 667 1713

---

## Educational Workshop on Epilepsy

**22nd International Epilepsy Congress**  
**27–28 JUNE 1997**  
**Trinity College, Dublin**

**Organised by the International Bureau for Epilepsy**

Aimed at young professionals including doctors, nurses and social workers, this workshop will bring together experts in the field to provide an overview of key clinical and psychosocial issues in epilepsy care. Invited speakers include Professor David Chadwick, Professor Jerome Engel, Ms Hanneke de Boer, Professor Pat Gibson. The workshop will cover:

- treatment issues
- systems of care

- the role of the multidisciplinary team
- family, educational and employment issues

**Cost:** £120 per person, to include registration, accommodation, lunch, tea and coffee.

**For further information, contact:**

Ann Jacoby  
University of Newcastle upon Tyne, UK  
Tel: 00 44 191 222 7046  
Fax: 00 44 191 222 6043  
e-mail: [ann.jacoby@ncl.ac.uk](mailto:ann.jacoby@ncl.ac.uk)

Jacqui Berkeley  
Incentive Conference Ireland  
Tel: 00 353 1 667 1711  
Fax: 00 353 1 667 1713

# Fourth Eilat Conference on New Antiepileptic Drugs

## September 6–10, 1998

### Royal Beach Hotel, Eilat, Israel

The program includes the following sessions:

**Session 1: *Outcome Assessment in Epilepsy: Methodology and Challenges***

1. Requirements for long-term efficacy outcome trials in epilepsy: Clinical perspective. C.E. Elger (Germany)
2. Health-related quality of life in epilepsy: Can it be measured? J. Cramer (USA)
3. Special problems related to the assessment of efficacy in infants and children. O. Dulac (France)
4. Limitations of the methods used to assess drug product safety and effectiveness: Regulatory perspectives. P. Leber (USA)
5. Limitations of the methods used to assess drug product safety and effectiveness: Clinical Perspectives. H. Meinardi (The Netherlands) and J.A. French (USA).

**Session 2: *Cost-Effectiveness Assessments: How and When? (Round Table)***

1. Regulatory perspectives
2. Clinical perspectives. S. Shorvon (UK)
3. Industry perspectives. S. Schwabe (Denmark) and H.C. Rohde (Denmark).

**Session 3: *Cost-Effectiveness of Recently Marketed Antiepileptic Drugs***

1. Controversial Views. Con: JWAS Sander (UK); Pro: B. Schmidt (Germany).

**Session 4: *Drugs in Development***

1. Remacemide
2. Rufinamide (CGP 33101)
3. Levetiracetam (ucb LO 59)
4. Losigamone
5. D2916
6. TV 1901
7. D-231291
8. Ganaxolone (CCD 1042).

**Session 5: *Progress Report On and Recent Findings of Marketed Drugs (monotherapy, assessment of relevant side effects, the use of these new AEDs in non-epileptic syndromes, etc.)***

1. Felbamate
2. Fosphenytoin
3. Gabapentin
4. Lamotrigine
5. Oxcarbazepine
6. Tiagabine
7. Topiramate
8. Vigabatrin
9. Zonisamide
10. Vagal Stimulation—a new antiepileptic device.

**Session 6: *Controversies in Strategies for Drug Development***

1. The case for pursuing selectivity of action. J.L. Noebels (USA)
2. The case for multiple mechanism of action. D. Schmidt (Germany)
3. Can we prevent epileptogenesis? M.A. Dichter (USA)
4. Prediction potential of preclinical models: lessons from the past. H.J. Kupferberg (USA)
5. Rational approach to the prediction of metabolic drug interactions: a practical guide for the clinician. R.H. Levy (USA)
6. Pharmacodynamic drug interactions: Can they be exploited to clinical benefit? L. Gram (Denmark).

A limited number of free papers (posters) are accepted on a first come—first in basis. Organizing Committee: M. Blaler, Israel; S.I. Johannessen, Norway; H.J. Kupferberg, USA; R.H. Levy, USA; P. Loiseau, France; E. Perucca, Italy.

Information: Conference Secretariat, P.O. Box 29041, Tel Aviv 61290, Israel.  
Tel: 972-3-5175149/50.  
Fax: 972-3-5175155.